Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma

Melanoma Manag. 2019 May 31;6(2):MMT20. doi: 10.2217/mmt-2018-0010.


Aim: Metastatic melanoma patients were treated with patient-specific vaccines consisting of autologous dendritic cells loaded with antigens from irradiated cells from short-term autologous tumor cell lines.

Patients & methods: A total of 72 patients were enrolled in a single-arm Phase I/II (NCT00948480) trial or a randomized Phase II (NCT00436930).

Results: Toxicity was minimal. Median overall survival (OS) was 49.4 months; 5-year OS 46%. A 5-year OS was 72% for 18 recurrent stage 3 without measurable disease when treated and 53% for 30 stage 4 without measurable disease when treated. A total of 24 patients with measurable stage 4 when treated (median of four prior therapies) had an 18.5 months median OS and 46% 2-year OS.

Conclusion: This dendritic cell vaccine was associated with encouraging survival in all three clinical subsets. NCT00436930 and NCT00948480.

Keywords: autologous tumor antigens; dendritic cells; melanoma; patient-specific therapy; therapeutic vaccine.

Publication types

  • Review

Associated data